Musculoskeletal Disorders Drugs Market Forecasts to 2030 – Global Analysis By Drug Type (Analgesics Corticosteroids and Other Drug Types), By Disorder Type (Fibromyalgia, Juvenile Idiopathic Arthritis, Osteoarthritis and Other Disorder Types), Treatment T

Musculoskeletal Disorders Drugs Market Forecasts to 2030 – Global Analysis By Drug Type (Analgesics Corticosteroids and Other Drug Types), By Disorder Type (Fibromyalgia, Juvenile Idiopathic Arthritis, Osteoarthritis and Other Disorder Types), Treatment Type (Medication, Surgery and Other Treatment Types), Route of Administration, Distribution Channel, End User, By Geography


According to Stratistics MRC, the Global Musculoskeletal Disorders Drugs Market is accounted for $88.6 billion in 2023 and is expected to reach $135.1 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Musculoskeletal disorder drugs are pharmaceuticals designed to treat conditions affecting the muscles, bones, joints, ligaments, and tendons. These disorders encompass a range of conditions, such as arthritis, osteoporosis, and musculoskeletal pain. The drugs aim to alleviate symptoms, manage inflammation, and modify disease progression, contributing to improved mobility and overall musculoskeletal health for individuals affected by these disorders.

According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries.

Market Dynamics:

Driver:

Rising prevalence of musculoskeletal disorders

The escalating prevalence of musculoskeletal disorders acts as a key driver in the musculoskeletal disorders drugs market. Factors such as aging populations, sedentary lifestyles, and an increase in chronic conditions contribute to a growing incidence of musculoskeletal issues like arthritis, osteoporosis, and musculoskeletal pain. This rising prevalence necessitates a corresponding surge in demand for effective pharmaceutical interventions. Consequently, pharmaceutical companies are prompted to invest in research and development, leading to the discovery and production of innovative drugs, thereby propelling the growth of the market.

Restraint:

Adverse side effects and high development costs

The occurrence of adverse effects associated with certain drugs can hinder patient compliance and acceptance. Additionally, the extensive research, development, and clinical trial processes contribute to elevated development costs. The financial burden of these costs may impede pharmaceutical companies from bringing novel and potentially groundbreaking musculoskeletal drugs to market promptly, limiting treatment options for patients impacting the overall growth and accessibility of effective therapies in the market.

Opportunity:

Surging demand for amyotrophic lateral sclerosis drugs

The increasing demand for amyotrophic lateral sclerosis drugs presents a notable opportunity in the musculoskeletal disorders drugs market. As awareness grows, there is a rising need for effective treatments to address this debilitating neurodegenerative disease. Pharmaceutical companies investing in amyotrophic lateral sclerosis drug development can tap into this expanding market, meeting the unmet medical needs of patients. Additionally, this contributes to the overall growth of the market.

Threat:

Insufficient availability of healthcare professionals

Musculoskeletal disorders often require specialized care, diagnosis, and treatment from healthcare professionals such as rheumatologists, orthopedic specialists, and physical therapists. The shortage of these professionals can result in delayed or inadequate patient care, hindering the proper identification and management of musculoskeletal disorders. This scarcity may lead to increased patient wait times, limited access to expert opinions, and challenges in implementing comprehensive treatment plans, affecting overall market growth.

Covid-19 Impact:

The COVID-19 pandemic has impacted the musculoskeletal disorder drug market in various ways. Lockdowns, disruptions in healthcare services, and economic uncertainties have influenced patient access to treatments. Delayed elective procedures and routine care appointments have affected drug consumption patterns. However, increased awareness of musculoskeletal health and the development of innovative telehealth solutions have partially mitigated these challenges during this period.

The juvenile idiopathic arthritis segment is expected to be the largest during the forecast period

The juvenile idiopathic arthritis segment is poised to dominate the musculoskeletal disorders drugs market during the forecast period due to the increasing incidence of juvenile idiopathic arthritis cases. Rising awareness, early diagnosis, and evolving treatment options contribute to the segment's growth. Pharmaceutical advancements, coupled with a focus on pediatric healthcare, drive research and development activities. Additionally, favorable regulatory support and initiatives for rare diseases further propel the prominence of the segment in the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital segment is primed for substantial growth in the musculoskeletal disorders drug market. Hospitals serve as key healthcare centers for musculoskeletal disorder diagnosis, treatment, and management. The increasing prevalence of these disorders, coupled with a rising aging population, drives the demand for specialized medical care. Additionally, combined with the expanding healthcare infrastructure, the hospital segment is poised for significant growth.

Region with largest share:

Over the forecast period, North America is expected to dominate the Musculoskeletal Disorders Drugs market due to the high prevalence of musculoskeletal disorders, an aging population, and a well-established healthcare infrastructure. Additionally, increasing awareness, advanced diagnostic capabilities, and robust research and development activities contribute to the market's growth. Moreover, the presence of major pharmaceutical companies and favorable reimbursement policies further solidify North America's position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for substantial growth in the Musculoskeletal Disorders Drugs market due to increasing aging populations, lifestyle changes, and a rising prevalence of musculoskeletal disorders. Additionally, improving healthcare infrastructure, growing awareness, and rising disposable incomes contribute to increased accessibility to advanced medications. Moreover, pharmaceutical companies are likely to expand their presence in the region, fostering significant growth in the musculoskeletal disorders drugs market.

Key players in the market

Some of the key players in Musculoskeletal Disorders Drugs Market include Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc.

Key Developments:

In Jun 2022, Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana’s microRNA targeting approach.

In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Drug Types Covered:
• Analgesics
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Other Drug Types

Disorder Types Covered:
• Fibromyalgia
• Juvenile Idiopathic Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Other Disorder Types

Treatment Types Covered:
• Medication
• Surgery
• Therapy
• Other Treatment Types

Route of Administrations Covered:
• Oral
• Parenteral
• Other Route of Administrations

Distribution Channels Covered:
• Hospital Pharmacy
• Online Providers
• Retail Pharmacy and Drug Stores
• Other Distribution Channels

End Users Covered:
• Diagnostic Centers
• Hospitals
• Rheumatologists
• Specialty Clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Musculoskeletal Disorders Drugs Market, By Drug Type
5.1 Introduction
5.2 Analgesics
5.3 Corticosteroids
5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
5.5 Other Drug Types
6 Global Musculoskeletal Disorders Drugs Market, By Disorder Type
6.1 Introduction
6.2 Fibromyalgia
6.3 Juvenile Idiopathic Arthritis
6.4 Osteoarthritis
6.5 Psoriatic Arthritis
6.6 Rheumatoid Arthritis
6.7 Spondylarthritis
6.8 Other Disorder Types
7 Global Musculoskeletal Disorders Drugs Market, By Treatment Type
7.1 Introduction
7.2 Medication
7.3 Surgery
7.4 Therapy
7.5 Other Treatment Types
8 Global Musculoskeletal Disorders Drugs Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Parenteral
8.4 Other Route of Administrations
9 Global Musculoskeletal Disorders Drugs Market, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacy
9.3 Online Providers
9.4 Retail Pharmacy and Drug Stores
9.5 Other Distribution Channels
10 Global Musculoskeletal Disorders Drugs Market, By End User
10.1 Introduction
10.2 Diagnostic Centers
10.3 Hospitals
10.4 Rheumatologists
10.5 Specialty Clinics
10.6 Other End Users
11 Global Musculoskeletal Disorders Drugs Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Pfizer Inc.
13.2 Novartis AG
13.3 Johnson & Johnson
13.4 Amgen Inc.
13.5 AbbVie Inc.
13.6 Roche Holding AG
13.7 Merck & Co., Inc.
13.8 Eli Lilly and Company
13.9 Sanofi
13.10 GlaxoSmithKline plc
13.11 Regeneron Pharmaceuticals, Inc.
13.12 Biogen Inc.
13.13 AstraZeneca plc
13.14 Bristol Myers Squibb Company
13.15 Takeda Pharmaceutical Company Limited
13.16 F. Hoffmann-La Roche Ltd.
13.17 Gilead Sciences, Inc.
List of Tables
Table 1 Global Musculoskeletal Disorders Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Musculoskeletal Disorders Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 3 Global Musculoskeletal Disorders Drugs Market Outlook, By Analgesics (2021-2030) ($MN)
Table 4 Global Musculoskeletal Disorders Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 5 Global Musculoskeletal Disorders Drugs Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN)
Table 6 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 7 Global Musculoskeletal Disorders Drugs Market Outlook, By Disorder Type (2021-2030) ($MN)
Table 8 Global Musculoskeletal Disorders Drugs Market Outlook, By Fibromyalgia (2021-2030) ($MN)
Table 9 Global Musculoskeletal Disorders Drugs Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
Table 10 Global Musculoskeletal Disorders Drugs Market Outlook, By Osteoarthritis (2021-2030) ($MN)
Table 11 Global Musculoskeletal Disorders Drugs Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
Table 12 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 13 Global Musculoskeletal Disorders Drugs Market Outlook, By Spondylarthritis (2021-2030) ($MN)
Table 14 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Disorder Types (2021-2030) ($MN)
Table 15 Global Musculoskeletal Disorders Drugs Market Outlook, By Treatment Type (2021-2030) ($MN)
Table 16 Global Musculoskeletal Disorders Drugs Market Outlook, By Medication (2021-2030) ($MN)
Table 17 Global Musculoskeletal Disorders Drugs Market Outlook, By Surgery (2021-2030) ($MN)
Table 18 Global Musculoskeletal Disorders Drugs Market Outlook, By Therapy (2021-2030) ($MN)
Table 19 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Treatment Types (2021-2030) ($MN)
Table 20 Global Musculoskeletal Disorders Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 21 Global Musculoskeletal Disorders Drugs Market Outlook, By Oral (2021-2030) ($MN)
Table 22 Global Musculoskeletal Disorders Drugs Market Outlook, By Parenteral (2021-2030) ($MN)
Table 23 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 24 Global Musculoskeletal Disorders Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 25 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 26 Global Musculoskeletal Disorders Drugs Market Outlook, By Online Providers (2021-2030) ($MN)
Table 27 Global Musculoskeletal Disorders Drugs Market Outlook, By Retail Pharmacy and Drug Stores (2021-2030) ($MN)
Table 28 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 29 Global Musculoskeletal Disorders Drugs Market Outlook, By End User (2021-2030) ($MN)
Table 30 Global Musculoskeletal Disorders Drugs Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
Table 31 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
Table 32 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatologists (2021-2030) ($MN)
Table 33 Global Musculoskeletal Disorders Drugs Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 34 Global Musculoskeletal Disorders Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings